Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Alzheimer's Disease

    San Diego, CA

    Search
    Alzheimer's Disease
    San Diego, CA
    Show Map
    Map View
    San Diego, CA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      77 Alzheimer's Disease Trials near San Diego, CA

      Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Gantenerumab for Alzheimer's Disease

      La Jolla, California
      The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Neurologic Disease, Psychiatric Disease, Stroke, Alcohol Use, Others
      Must Not Be Taking:Immunosuppressives, Anticoagulants

      280 Participants Needed

      Investigational Alzheimer's Drugs for Early Onset Alzheimer's Disease

      La Jolla, California
      This trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Neurologic, Psychiatric, Substance Use, Others
      Must Not Be Taking:Anticoagulants, Monoclonal Antibodies

      197 Participants Needed

      Disease-Modifying Drugs for Alzheimer's Disease

      La Jolla, California
      The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Alcohol/drug Dependence, Cardiovascular Disease, Others
      Must Not Be Taking:Anticoagulants, Monoclonal Antibodies

      490 Participants Needed

      Lecanemab for Alzheimer's Disease

      La Jolla, California
      This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cancer, Uncontrolled Hypertension, Others
      Must Be Taking:Anti-amyloid Therapy

      43 Participants Needed

      CPAP Therapy for Alzheimer's Disease

      La Jolla, California
      Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment. Sleep apnea is a form of sleep disruption. We would like to examine how obstructive sleep apnea may contribute to the progression of Alzheimer's disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:65 - 85

      Key Eligibility Criteria

      Disqualifiers:Smoking, COPD, Heart Failure, Neuromuscular Disease, Others

      260 Participants Needed

      AAV2-BDNF Gene Therapy for Alzheimer's Disease

      La Jolla, California
      This trial tests a new gene therapy that uses a virus to deliver a protective protein called BDNF into the brains of people with early Alzheimer's Disease and Mild Cognitive Impairment. The goal is to help brain cells survive, function better, and form new connections. The therapy aims to slow or prevent further brain cell loss. Brain-derived neurotrophic factor (BDNF) has been explored for its potential to support neuron survival and function in neurodegenerative diseases.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Neurological Disease, Major Depression, Cancer, Others
      Must Be Taking:Anti-cholinesterases, Memantine

      12 Participants Needed

      Nicotine Patch for Mild Cognitive Impairment

      San Diego, California
      The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Tobacco Use, Neurologic Disease, Major Depression, Others
      Must Be Taking:Memantine, Cholinesterase Inhibitors

      380 Participants Needed

      CBD + THC for Agitation in Dementia

      Chula Vista, California
      This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximately 120 participants of any gender at least 40 years of age who are hospice care-eligible with agitation and dementia (HAD). Participants will be randomized (50:50) to either active study drug (T2:C100) or placebo. The double-blind period of this study is 12 weeks. A 12 week optional open-label extension will be offered to participants who complete the double-blind period.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Cannabinoid Allergy, Investigational Drugs, Others
      Must Not Be Taking:Cannabinoids

      120 Participants Needed

      AVP-786 for Agitation in Alzheimer's Disease

      La Jolla, California
      This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Non-Alzheimer's Dementia, Unstable Systemic Diseases, Myasthenia Gravis, Others

      183 Participants Needed

      ATI-045 for Eczema

      Encinitas, California
      This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Anaphylaxis, Corticosteroid Allergy, Others
      Must Not Be Taking:Antibiotics, Corticosteroids, Biologics, Others

      96 Participants Needed

      Buntanetap for Alzheimer's Disease

      San Marcos, California
      The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      760 Participants Needed

      KarXT for Alzheimer's-Associated Psychosis

      San Marcos, California
      This trial is testing KarXT, a medication, to see if it can prevent psychotic symptoms from returning in people with Alzheimer's Disease. It works by balancing brain chemicals that cause hallucinations and delusions. KarXT has shown positive results in reducing symptoms of schizophrenia.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Severe Renal Impairment, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      380 Participants Needed

      ONO-2020 for Alzheimer's Disease

      Carlsbad, California
      This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Stroke, Schizophrenia, HIV, Others
      Must Be Taking:Acetylcholinesterase Inhibitors, Memantine

      240 Participants Needed

      Xanamem for Alzheimer's Disease

      Carlsbad, California
      Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Non-AD Dementia, Major Mental Illness, Diabetes, Others
      Must Be Taking:Symptomatic AD Medications

      220 Participants Needed

      Mevidalen for Alzheimer's Disease

      Carlsbad, California
      The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Childbearing Potential, CNS Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors, Inducers

      300 Participants Needed

      Care Program for Dementia Caregivers

      Carlsbad, California
      The purpose of the study is to develop and test the feasibility of a nonmedical digital health intervention, the Spanish-language Caregiver-Enabled Care Program (CECP), with Spanish-speaking caregivers of persons with dementia (PWD). CECP is a nonmedical digital population health intervention that provides personalized education, proactive 1:1 human coaching, and remote monitoring, all delivered via a dedicated tablet shipped to the caregiver's home at no cost to the caregiver or PWD. For this study, the investigators are recruiting 135 patient/caregiver dyads.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Disenrollment Plans, Others

      270 Participants Needed

      ALZ-801 for Early Alzheimer's Disease

      Costa Mesa, California
      This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Moderate-severe ARIA, Others
      Must Not Be Taking:Amyloid Antibodies

      163 Participants Needed

      MRI + PET Scans for Cognitive Impairment

      Irvine, California
      The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others

      300 Participants Needed

      Screening for Alzheimer's Disease Studies

      Irvine, California
      This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Neurological Conditions, CNS Trauma, Others

      13000 Participants Needed

      Trontinemab for Alzheimer's Disease

      Irvine, California
      The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Cerebrovascular Disease, CNS Trauma, Others

      800 Participants Needed

      Why Other Patients Applied

      "I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

      VL
      Alzheimer's PatientAge: 71

      "I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

      AH
      Dementia PatientAge: 64

      "I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

      OF
      Alzheimer's Disease PatientAge: 65

      "I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

      EK
      Mild Cognitive Impairment PatientAge: 72

      "I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

      WU
      Healthy Volunteer PatientAge: 76
      Match to a Alzheimer's Disease Trial

      KarXT for Psychosis in Alzheimer's Disease

      Costa Mesa, California
      The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others

      406 Participants Needed

      ACP-204 for Alzheimer's Disease

      Costa Mesa, California
      This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:55 - 95

      Key Eligibility Criteria

      Disqualifiers:Hospice Care, Bedridden, Pregnancy, Others
      Must Not Be Taking:Prohibited Medications

      752 Participants Needed

      KarXT for Alzheimer's-Related Psychosis

      Costa Mesa, California
      This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026 or CN012-0027. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 or CN012-0027 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Severe Medical Conditions, Others

      300 Participants Needed

      MK-2214 for Alzheimer's Disease

      Irvine, California
      Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Stroke, Seizures, CNS Disease, Others
      Must Not Be Taking:Biologics, Immunosuppressants

      340 Participants Needed

      MK-1167 for Alzheimer's Disease

      Irvine, California
      Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About the safety of MK-1167 and if people tolerate it

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Stroke, CNS Disease, Seizures, Others
      Must Be Taking:Acetylcholinesterase Inhibitors

      350 Participants Needed

      ITI-1284 for Psychosis in Alzheimer's Disease

      Costa Mesa, California
      This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55+

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Suicide Risk, Others
      Must Not Be Taking:Psychotropics, CNS Drugs

      370 Participants Needed

      CT1812 for Early Alzheimer's Disease

      Irvine, California
      This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Other Dementias, Neurodegenerative Conditions, Hepatitis, Others

      540 Participants Needed

      PMN310 for Alzheimer's Disease

      Irvine, California
      This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Huntington's, Stroke, Others
      Must Be Taking:Acetylcholinesterase Inhibitors, Memantine

      128 Participants Needed

      Stem Cell Therapy for Alzheimer's Disease

      Newport Beach, California
      This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:45 - 80

      Key Eligibility Criteria

      Disqualifiers:Neurological, Psychiatric, Cancer, Others
      Must Be Taking:Donepezil, Memantine, AChEIs

      18 Participants Needed

      Alzheimer's Disease Vaccine for Alzheimer's Disease

      Newport Beach, California
      Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:Insulin-dependent Diabetes, Autoimmune Diseases, Others
      Must Be Taking:Acetylcholine Esterase Inhibitors, Memantine

      48 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Alzheimer's Disease clinical trials in San Diego, CA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Alzheimer's Disease clinical trials in San Diego, CA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Alzheimer's Disease trials in San Diego, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in San Diego, CA for Alzheimer's Disease is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in San Diego, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Alzheimer's Disease medical study in San Diego, CA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Alzheimer's Disease clinical trials in San Diego, CA?

      Most recently, we added KarXT + KarX-EC for Alzheimer's Disease, Trontinemab for Alzheimer's Disease and Trontinemab for Alzheimer's Disease to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in California

      Anxiety Clinical Trials in California

      Schizophrenia Clinical Trials in California

      ADHD Clinical Trials in California

      Bipolar Disorder Clinical Trials in California

      Multiple Sclerosis Clinical Trials in California

      Autism Clinical Trials in California

      Treatment Resistant Depression Clinical Trials in California

      Borderline Personality Disorder Clinical Trials in California

      Social Anxiety Disorder Clinical Trials in California

      Parkinson's Disease Clinical Trials in California

      Alzheimer's Disease Clinical Trials in California

      By Location

      Clinical Trials near Los Angeles, CA

      Clinical Trials near San Francisco, CA

      Clinical Trials near San Diego, CA

      Clinical Trials near Sacramento, CA

      Clinical Trials near La Jolla, CA

      Clinical Trials near Orange, CA

      Clinical Trials near Stanford, CA

      Clinical Trials near Palo Alto, CA

      Clinical Trials near Long Beach, CA

      Clinical Trials near Duarte, CA

      Clinical Trials near Oakland, CA

      Clinical Trials near Torrance, CA

      Other People Viewed

      By Subject

      45 Alzheimer's Disease Trials near San Francisco, CA

      83 Alzheimer's Disease Trials near San Antonio, TX

      76 Alzheimer's Disease Trials near Anaheim, CA

      77 Alzheimer's Disease Trials near Los Angeles, CA

      74 Alzheimer's Disease Trials near Ventura, CA

      48 Psoriasis Trials near San Diego, CA

      16 Celiac Disease Trials near San Diego, CA

      38 Retinitis Pigmentosa Trials near San Diego, CA

      79 Osteoporosis Trials near San Diego, CA

      Top Clinical Trials near San Diego, CA

      Top Lymphedema Clinical Trials near San Diego, CA

      Top Weight Loss Clinical Trials near San Diego, CA

      By Trial

      Xanomeline + Trospium for Agitation in Alzheimer's Disease

      KarXT + KarX-EC for Agitation in Alzheimer's Disease

      AVP-786 for Agitation in Alzheimer's Disease

      JNJ-63733657 for Alzheimer's Disease

      Treadmill Training for Mild Cognitive Impairment and Alzheimer's Disease

      Icosapent Ethyl for Alzheimer's Disease

      Virtual Reality for Upper Limb Rehabilitation After Stroke

      Accelerated Rehabilitation for Rotator Cuff Tears

      ICG Dye to Reduce Fistulas After Throat Cancer Surgery

      99mTc-ECDG for Coronary Artery Disease

      P-15L Bone Graft for Degenerative Disc Disease

      Nerofe for Acute Myeloid Leukemia and Myelodysplastic Syndrome

      Related Searches

      Top Benign-prostatic-hyperplasia Clinical Trials

      Top Weight-loss Clinical Trials near San Diego, CA

      Atezolizumab for High-Risk Bladder Cancer

      Vancomycin Dosing for MRSA Infections

      JASPER Therapy for Down Syndrome

      Novel Healthcare Approaches for Delirium in Elders

      Transcranial Magnetic Stimulation for Episodic Memory

      PBGENE-HBV for Chronic Hepatitis B

      SAFPAS App for Improving Healthy Food Access

      THC for Cannabis Intoxication

      VRDN-001 for Thyroid Eye Disease

      ABBV-668 for Ulcerative Colitis